ARROWHEAD PHARMACEUTICALS, INC. cotiza a 58.13 USD y tiene una capitalización bursátil de $8.2B. En los últimos 12 meses ha facturado $669M con un margen de flujo de caja libre del 18.9%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a d…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.36 | $-0.93 | $0.22 |
| Estimado | $-1.54 | $-1.23 | $-1.11 | $-0.37 |
| Sorpresa | — | -10.6% | +16.2% | +159.5% |
| Métrica | ARWR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 11.9% | -38.6% | +50.5% |
| Net Margin | -0.2% | -33.6% | +33.4% |
| FCF Margin | 18.9% | -13.9% | +32.8% |
| ROE | -0.3% | -40.4% | +40.0% |
| ROA | -0.1% | -32.0% | +31.9% |
| Current Ratio | 4.86 | 2.84 | +2.02 |
| Debt / Equity | — | 0.28 | — |